Global Bioprocess Automation Software Market Revenue Grows at a CAGR of 8.58%

Introduction

Straits Research released its highly anticipated report, “Global Bioprocess Automation Software Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 4.58 billion in 2025 and is anticipated to grow to USD 9.58 billion by 2034, growing at a CAGR of 8.58% from 2026-2034.

Market Dynamics

A key driver for the bioprocess automation software market is the rising shift toward digital production environments that support consistent oversight of upstream and downstream workflows through unified control platforms, allowing facilities to manage complex biologics pipelines with greater coordination across equipment and data systems. A restraint for the market emerges from integration challenges linked to legacy hardware, varied communication protocols, and inconsistent digital maturity across manufacturing sites, which slows the adoption of advanced automation suites in older infrastructure. An opportunity arises from the expanding use of AI-based deviation prediction and smart analytics tools that enable early identification of process shifts, encouraging broader adoption of software systems that enhance real-time decision making across development and commercial bioproduction settings.

Market Highlights

• Type: The Process Analytical Technology (PAT) segment dominates the market in 2025 with a share of 32.35%.
• Application: Downstream Processing dominates the market in 2025 with a share of 36.78%.
• End User: Biopharmaceutical Companies dominate the market in 2025 with a share of 42.32%.
• Regional Insights: North America held a dominant share of the global market, accounting for 42.78%.

Competitive Players

1. Thermo Fisher Scientific Inc.
2. Merck KGaA
3. Sartorius AG
4. Cytiva
5. Danaher Corporation
6. Eppendorf SE
7. GE HealthCare
8. ABB
9. Rockwell Automation
10. Siemens Healthineers AG
11. Agilent Technologies, Inc.
12. Waters Corporation
13. Repligen Corporation
14. Corning Incorporated
15. Parker Hannifin Corp
16. BD
17. Lonza
18. SECURECELL AG
19. Others

Recent Developments

October 2025: Fusion Antibodies secured a multi-target antibody humanisation project with a European pharmaceutical firm, highlighting growing demand for antibody optimisation services to advance complex VHH-based therapeutic programmes.

Segmentation

1. By Type (2026-2034)
   1. Distributed Control Systems (DCS)
   2. Supervisory Control and Data Acquisition (SCADA)
   3. Manufacturing Execution Systems (MES)
   4. Laboratory Information Management Systems (LIMS)
   5. Process Analytical Technology (PAT)
2. By Application (2026-2034)
   1. Upstream Processing
   2. Downstream Processing
   3. Quality Control
   4. Manufacturing Operations
   5. Data Management
3. By End-User (2026-2034)
   1. Biopharmaceutical Companies
   2. Contract Manufacturing Organizations (CMOs)
   3. Research and Development Laboratories
   4. Academic and Research Institute